Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of FUNDC1 in preparation of medicine for preventing and treating vascular and tumor diseases

A FUNDC1, 1.FUNDC1 technology, applied in the FUNDC1 application field, can solve the problem that the effect needs to be improved

Inactive Publication Date: 2021-07-27
XIEHE HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI & TECH UNIV
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] In order to solve the above problems, the present invention provides the use of FUNDC1 in the preparation of drugs for the prevention and treatment of blood vessels and tumor diseases, which mainly solves the blank application of FUNDC1 as a target in anti-tumor drugs, and the effect of existing anti-tumor angiogenesis drugs needs to be improved.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of FUNDC1 in preparation of medicine for preventing and treating vascular and tumor diseases
  • Application of FUNDC1 in preparation of medicine for preventing and treating vascular and tumor diseases
  • Application of FUNDC1 in preparation of medicine for preventing and treating vascular and tumor diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0053] figure 1 Middle A is an 8-week-old male C57BL / 6 mouse, which was given control (Ad-Null) and FUNDC1 overexpressed adenovirus (Ad-FUNDC1) respectively, injected into the tail vein of the mouse, and then the tumor cell suspension was inoculated subcutaneously on the back of the mouse . The size of the solid tumor was measured on the fifth day, ninth day, fourteenth day and sixteenth day after inoculation. figure 1 Middle B is the statistical chart of the change of tumor size in mice in A.

[0054] Depend on figure 1 In A and B, it can be seen that compared with the control treatment group, on the ninth day, fourteenth day, and sixteenth day after inoculation, the solid tumor volume of mice in the overexpression FUNDC1 group has a significant increase, and overexpression FUNDC1 promotes tumor growth. growth.

[0055] figure 1 Middle C is 8-week-old male C57BL / 6 background FUNDC1 knockout control (FUNDC1flox / flox group) mice and endothelial-specific FUNDC1 knockout (FU...

Embodiment 2

[0059] Eight-week-old male C57BL / 6 mice were given control (Ad-Null) and FUNDC1 overexpressed adenovirus (Ad-FUNDC1) and subcutaneously inoculated tumors. The mice were sacrificed on the 16th day after inoculation, and the tumor tissues of the mice were collected. , The expression level of CD31 protein was detected by immunofluorescence technique.

[0060] figure 2 Middle A is the immunofluorescence image, CD31 protein expression, and related expression statistics;

[0061] Depend on figure 2 In middle A, it can be seen that the protein expression level of CD31 in the tumor tissue was significantly increased in the subcutaneously transplanted tumor overexpressing FUNDC1 group.

[0062] Eight-week-old male C57BL / 6 background FUNDC1 knockout control (FUNDC1flox / flox group) mice and endothelial-specific knockout FUNDC1 (FUNDC1 ECKO) mice were subcutaneously inoculated with tumors, and the mice were sacrificed on the 14th day after inoculation. The mouse tumor tissues were ta...

Embodiment 3

[0066] After HUVEC cells were treated with siRNA knockdown control, siRNA knockdown FUNDC1, adenovirus control and adenovirus overexpression FUNDC1, the proliferation of HUVEC was detected by EdU assay.

[0067] image 3 Middle A is the siRNA knockdown control group (si-Control group) and the siRNA knockdown FUNDC1 treatment group (siFUNDC1) using EdU assay to detect the proliferation of human umbilical vein endothelial cells (HUVEC). The first column is the siRNA knockdown control group (si-Control group), and the second column is the siRNA knockdown FUNDC1 treatment group (siFUNDC1).

[0068] image 3 Middle B is the statistical graph of HUVEC proliferation detected by EdU assay in siRNA knockdown control group (si-Control group) and siRNA knockdown FUNDC1 treatment group (siFUNDC1).

[0069] Depend on image 3 In A and B, it can be seen that knocking down FUNDC1 can inhibit the proliferation of HUVEC cells.

[0070] image 3 Middle C is the adenovirus control group (Nu...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to research in the field of FUNDC1 application, and particularly discloses application of FUNDC1 in preparation of drugs for preventing and treating vascular and tumor diseases. The invention relates to an application of an FUNDC1 inhibitor in preparation of medicines for preventing and treating tumor diseases. The medicine for preventing and treating tumor diseases comprises an FUNDC1 inhibitor, preferably short peptide P, as an effective component. The invention relates to an application of a VEGFR2 molecular signal channel inhibitor in preparation of anti-tumor angiogenesis drugs. An effective component of the VEGFR2 molecular signal channel inhibition drug comprises an FUNDC1 inhibitor, and preferably, the FUNDC1 inhibitor is an oligopeptide P. The invention relates to an application of FUNDC1 in preparation of a medicine for promoting angiogenesis. The medicine for promoting blood vessel production comprises an active ingredient FUNDC1, preferably, the medicine is a medicine for promoting proliferation and / or migration of HUVEC cells. The invention relates to FUNDC1 inhibitors for preventing or treating onset and development of tumors; and the FUNDC1 can also be widely applied as a medicine for treating diseases such as retinal angiogenesis and vascular injury participated by endothelial cells.

Description

technical field [0001] The invention belongs to the field of research on the application of FUNDC1, and in particular relates to the use of FUNDC1 in the preparation of drugs for preventing and treating blood vessel and tumor diseases. Background technique [0002] Mitophagy receptor protein (FUNDC1) is a highly conserved mitochondrial outer membrane protein widely expressed in various cells, tissues and organs. As a mitophagy receptor, it mediates mitophagy by interacting with LC3. Under normal stress conditions, FUNDC1 is phosphorylated by SRC kinase and casein kinase 2, reducing its affinity for LC3. Under stress conditions such as hypoxia and mitochondrial membrane decoupler treatment, FUNDC1 is phosphorylated at its serine 17 by unc-51-like autophagy kinase and dephosphorylated at its serine 13 by phosphoglycerate mutase 5 Activation enhances the binding of its LIR to LC3 and promotes mitophagy. In MAM, FUNDC1 can interact with IP3R2 to regulate the release of ER Ca2...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/00A61K38/02A61K48/00A61K31/713A61P9/10A61P27/02A61P9/14
CPCA61K45/00A61K38/02A61K31/713A61P9/10A61P27/02A61P9/14
Inventor 王成
Owner XIEHE HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI & TECH UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com